Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance.

AbbVie continues to develop portfolio diversification to adjust to increased competition for top-seller Humira.

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...

AbbVie Inc. lifted its full-year profit guidance as newer anti-inflammatory treatments like Rinvoq and Skyrizi take over for ...

AbbVie's shares dropped last week due to concerns about Humira erosion and despite ABBV beating revenue and EPS expectations.

AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug ...

AbbVie on Friday reported first-quarter results that beat expectations even as sales of its blockbuster autoimmune drug ...

AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective ...

AbbVie Inc. plans to lean financially on increasing sales for several drugs in its stable, such as its Skyrizi medicine, to ...

AbbVie's earnings beat estimates, with a smaller decline in Humira sales. Read how the biotech's next-generation drugs Rinvoq ...

AbbVie’s net revenue from its immunology portfolio dropped nearly 4% to $5.3 billion due to increased Humira biosimilar ...

(Reuters) -AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as patients shift to other drugs.